AEZS-108: Additional Phase II data

Data from 39 evaluable patients with LHRH-positive endometrial cancer from the open-label, European Phase II AGO-GYN-5 trial showed that IV 267 mg/m 2 AEZS-108 every 3 weeks produced an ORR of 30.8%, including 2 complete responses and 10 partial responses, plus 17 cases of stable disease. Median TTP and OS were 7 and 14.3 months, respectively. AEZS-108 was well tolerated with no cardiac toxicity reported. Data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Berlin. ...